20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

The Role of BKM120 in Fibrosis Research: Mechanisms and Sourcing

Fibrosis, the excessive accumulation of extracellular matrix, is a pathological process underlying organ damage and failure in numerous chronic diseases, including liver fibrosis, lung fibrosis, and kidney fibrosis. While inflammation plays a crucial role in initiating and propagating fibrotic responses, the precise molecular mechanisms are complex. Research into novel therapeutic strategies to combat fibrosis often focuses on modulating inflammatory pathways and cellular signaling cascades. In this context, compounds like BKM120 (CAS 944396-07-0) are proving to be valuable research tools.

BKM120, known for its potent and selective inhibition of the PI3K pathway, has demonstrated utility beyond cancer research. Specifically, it can suppress the production of pro-inflammatory cytokines and chemokines. These signaling molecules are key drivers in the inflammatory milieu that promotes fibroblast activation and extracellular matrix deposition, hallmarks of fibrosis. By mitigating this inflammatory cascade, BKM120 can offer a pathway to understanding and potentially treating fibrotic conditions. Researchers looking to buy PI3K inhibitor BKM120 for fibrosis studies need access to a reliable supply of high-quality material.

As a leading pharmaceutical intermediate manufacturer in China, we are a trusted source for BKM120. Our commitment to producing compounds with high purity ensures that your research into the inflammatory components of fibrosis yields accurate and reproducible results. We understand the importance of consistent quality when you procure Buparlisib for drug discovery or related research. We are a dedicated CAS 944396-07-0 supplier in China, offering competitive pricing and a stable supply chain.

For procurement managers and research scientists, securing research chemicals like BKM120 requires a partner who prioritizes quality and reliability. We offer a transparent process for obtaining the necessary product information, including Certificates of Analysis, and maintain a focus on providing an excellent BKM120 price for research. Partner with us to acquire the essential chemical intermediates needed to advance your critical fibrosis research.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: BKM120 in Action: Advancing Cancer Research with PI3K Inhibition

Next: BKM120 (Buparlisib): A PI3K Inhibitor for Cell Signaling Research

All Rights Reserved